Kite assesses EU manufacturing options as it submits CAR-T therapy for review – BioPharma-Reporter.com
|
Kite assesses EU manufacturing options as it submits CAR–T therapy for review
BioPharma-Reporter.com The submission is the first in Europe of a chimeric antigen receptor (CAR) T-cell therapy and as such Kite is now evaluating manufacturing options in Europe, a spokesperson from the firm told Biopharma-Reporter. Kite's principle manufacturing facility … |
